What migraine preventive medication is appropriate for an adult patient who cannot use vasoconstrictive agents?

Migraine Prevention for Patients Who Cannot Use Vasoconstrictive Agents

For adult patients who cannot use vasoconstrictive agents (triptans, ergots), initiate preventive therapy with CGRP monoclonal antibodies (erenumab, fremanezumab, or galcanezumab) as first-line treatment, or alternatively use candesartan, topiramate, or amitriptyline based on comorbidities. 1, 2

Primary Recommendation: CGRP-Targeting Therapies

The 2025 American College of Physicians guideline explicitly includes CGRP monoclonal antibodies among first-line preventive options for episodic migraine 1. The VA/DoD 2024 guideline gives a strong recommendation for erenumab, fremanezumab, or galcanezumab for prevention of both episodic and chronic migraine 2. These agents are particularly advantageous because:

• They are migraine-specific and do not cause vasoconstriction
• They have superior tolerability compared to traditional preventives
• They demonstrate high-quality evidence for efficacy on morbidity and quality of life outcomes 3

Injectable CGRP monoclonal antibodies (monthly or quarterly dosing):

• Erenumab 70-140 mg SC monthly
• Fremanezumab 225 mg SC monthly or 675 mg SC quarterly
• Galcanezumab 240 mg SC loading dose, then 120 mg monthly
• Eptinezumab 100 mg IV quarterly (weak recommendation) 2

Alternative First-Line Options

Angiotensin Receptor Blockers (Preferred Non-CGRP Option)

Candesartan or telmisartan receive strong recommendations from the VA/DoD guideline for episodic migraine prevention 2. These are particularly suitable because:

• No vasoconstrictive properties
• Excellent for patients with comorbid hypertension
• Well-tolerated with minimal adverse effects
• Candesartan: 16 mg daily
• Telmisartan: 80 mg daily

Antiepileptic Medications

Topiramate receives weak recommendations but has substantial evidence for both episodic and chronic migraine 2. Key considerations:

• Start 25 mg daily, titrate slowly to 50-100 mg twice daily
• Avoid in patients desiring pregnancy (teratogenic)
• Common side effects: paresthesias, cognitive slowing, weight loss
• Useful when weight loss is desired

Valproate (weak recommendation) is effective but has significant limitations:

• Contraindicated in pregnancy (highly teratogenic)
• Weight gain, tremor, hair loss common
• Requires monitoring for hepatotoxicity 2

Tricyclic Antidepressants

Amitriptyline is included in the ACP guideline evaluation 1 and has long-standing evidence:

• Start 10-25 mg at bedtime, titrate to 50-150 mg
• Particularly useful with comorbid insomnia, anxiety, or chronic pain
• Avoid in elderly due to anticholinergic effects
• Contraindicated with cardiac conduction abnormalities

ACE Inhibitors

Lisinopril receives a weak recommendation for episodic migraine 2:

• 10-20 mg daily
• Alternative to ARBs for patients with hypertension
• Generally well-tolerated

Oral CGRP Antagonists (Gepants)

Atogepant (weak recommendation) is an oral option for episodic migraine prevention 2:

• 10 mg, 30 mg, or 60 mg once daily
• Useful for patients preferring oral medication over injections
• Dose adjustment needed with severe hepatic impairment or strong CYP3A4 inhibitors

Rimegepant has insufficient evidence for a formal recommendation but is FDA-approved 2:

• 75 mg every other day
• Can also be used for acute treatment

Clinical Algorithm for Selection

Step 1: Assess comorbidities

• Hypertension → Candesartan/telmisartan or lisinopril
• Depression/anxiety → Amitriptyline or venlafaxine
• Obesity/desire for weight loss → Topiramate
• Insomnia → Amitriptyline

Step 2: Consider patient preferences

• Prefer injections with minimal side effects → CGRP mAbs
• Prefer oral medication → Candesartan, topiramate, or atogepant
• Cost-sensitive/insurance limitations → Start with candesartan or amitriptyline

Step 3: Contraindications to avoid

• Pregnancy potential → Avoid topiramate and valproate
• Elderly patients → Avoid amitriptyline (anticholinergic burden)
• Cardiac disease → Avoid amitriptyline
• Hypotension → Avoid candesartan/telmisartan/lisinopril

Critical Pitfalls

Do not use beta-blockers (propranolol, metoprolol) in patients who cannot tolerate vasoconstrictive agents if the contraindication is cardiovascular, as beta-blockers can worsen peripheral vascular disease, heart failure, and certain arrhythmias 2, 4.

Avoid triptans and ergots entirely - these are acute treatments with vasoconstrictive properties and are contraindicated in your patient population.

Ensure adequate trial duration: Allow 2-3 months at therapeutic dose before declaring treatment failure, except for CGRP mAbs which may show benefit within 1 month 5.

Treatment Failure Strategy

If initial monotherapy fails after adequate trial:

1. Switch to alternative first-line agent from different class
2. Consider combination therapy (e.g., CGRP mAb + candesartan)
3. Refer to headache specialist for refractory cases 1

The evidence strongly supports CGRP-targeting therapies as transformational with superior adherence and tolerability compared to traditional preventives 3, 6, making them the optimal choice when accessible, particularly for patients with contraindications to vasoconstrictive agents.